These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35303463)

  • 41. Psychological distress and its effect on tuberculosis treatment outcomes in Ethiopia.
    Tola HH; Shojaeizadeh D; Garmaroudi G; Tol A; Yekaninejad MS; Ejeta LT; Kebede A; Karimi M; Kassa D
    Glob Health Action; 2015; 8():29019. PubMed ID: 26610316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of multidrug resistant tuberculosis among adult patients at Saint Peter Hospital Addis Ababa, Ethiopia.
    Dessalegn M; Daniel E; Behailu S; Wagnew M; Nyagero J
    Pan Afr Med J; 2016; 25(Suppl 2):5. PubMed ID: 28439330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between body mass index and newly diagnosed drug-resistant pulmonary tuberculosis in Shandong, China from 2004 to 2019.
    Song WM; Guo J; Xu TT; Li SJ; Liu JY; Tao NN; Liu Y; Zhang QY; Liu SQ; An QQ; Li YF; Yu CB; Dong JH; Li HC
    BMC Pulm Med; 2021 Dec; 21(1):399. PubMed ID: 34872558
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands.
    Gafar F; Van't Boveneind-Vrubleuskaya N; Akkerman OW; Wilffert B; Alffenaar JC
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31515410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES
    BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients: A 6-Year Retrospective Study from Pakistan.
    Khan FU; Rehman AU; Khan FU; Hayat K; Khan A; Ahmad N; Chang J; Malik UR; Fang Y
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.
    Kapata N; Chanda-Kapata P; Bates M; Mwaba P; Cobelens F; Grobusch MP; Zumla A
    Trop Med Int Health; 2013 Nov; 18(11):1386-91. PubMed ID: 24033538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
    Bhering M; Duarte R; Kritski A
    Int J Tuberc Lung Dis; 2021 Apr; 25(4):292-298. PubMed ID: 33762073
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study.
    Zheng XB; Diwan VK; Zhao Q; Hu Y; Bruchfeld J; Jiang WL; Hoffner S; Xu B
    Infect Dis Poverty; 2020 Jul; 9(1):97. PubMed ID: 32682446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up.
    Yu MC; Chiang CY; Lee JJ; Chien ST; Lin CJ; Lee SW; Lin CB; Yang WT; Wu YH; Huang YW
    Clin Infect Dis; 2018 Jul; 67(2):202-210. PubMed ID: 29394358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study.
    Tola H; Holakouie-Naieni K; Mansournia MA; Yaseri M; Gamtesa DF; Tesfaye E; Mahamed Z; Sisay MM
    BMJ Open; 2021 Aug; 11(8):e040862. PubMed ID: 34376436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia.
    Abdella K; Abdissa K; Kebede W; Abebe G
    BMC Public Health; 2015 Jul; 15():599. PubMed ID: 26135909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.
    van Altena R; de Vries G; Haar CH; de Lange WC; Magis-Escurra C; van den Hof S; van Soolingen D; Boeree MJ; van der Werf TS
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):406-12. PubMed ID: 25859995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.
    Bastard M; Sanchez-Padilla E; du Cros P; Khamraev AK; Parpieva N; Tillyashaykov M; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Perez SF; Telnov A; Hewison C; Varaine F; Bonnet M
    PLoS One; 2018; 13(3):e0193491. PubMed ID: 29518098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.